Equities

Beijing Luzhu Biotechnology Co Ltd

Beijing Luzhu Biotechnology Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)20.85
  • Today's Change-0.10 / -0.48%
  • Shares traded6.40k
  • 1 Year change-38.86%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:21 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Beijing Luzhu Biotechnology Co Ltd is a China-based company principally engaged in drug discovery, research and development and commercialization. The Company is also engaged in out-licensing human vaccines and therapeutic biologics. Its products under clinical development include recombinant herpes zoster vaccine LZ901, and antibody injection products K3 and K193. Its LZ901 is mainly used to prevent herpes zoster caused by varicella zoster virus in adults aged 50 and above. The Company operates in the domestic market and overseas markets.

  • Revenue in HKD (TTM)0.00
  • Net income in HKD-300.71m
  • Incorporated2001
  • Employees148.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Medincell SA73.63m-204.11m4.09bn134.00------55.55-0.8754-0.87540.3178-1.400.2725--5.9967,402.98-75.54-61.75---167.6174.9271.74-277.21-366.40---5.233.25---8.6744.3321.78--9.57--
SNDL Inc5.08bn-615.28m4.09bn2.52k--0.6076--0.8059-0.3017-0.30172.483.260.60624.9836.38259,248.20-7.61-24.44-8.22-27.9425.6922.49-12.55-62.174.16--0.114--27.63--49.83------
Hunan Warrant Pharmaceutical Co Ltd1.56bn227.39m4.17bn1.16k18.342.06--2.682.252.2515.4220.060.64261.499.741,244,707.008.3411.219.7914.0561.3269.0012.9813.963.18--0.05668.0510.8418.5015.6019.0224.49--
Beijing Luzhu Biotechnology Co Ltd0.00-300.71m4.21bn148.00--4.18-----1.49-1.490.005.010.00----0.00-23.80---25.44----------5.91--0.0296------65.62------
Boiron SA3.93bn193.13m4.22bn2.79k21.621.3712.221.071.361.3627.7421.480.73521.296.19171,427.803.424.594.215.7672.8474.024.656.801.37--0.038353.86-7.67-3.98-19.80-9.01-17.68-1.42
Pharmanutra SpA914.97m132.64m4.24bn119.0031.718.7625.204.631.691.6911.686.131.010.67074.571,068,933.0014.6018.3919.3424.8095.2896.3614.5017.771.9839.840.293652.5121.1316.51-14.738.4475.7111.20
ASP Isotopes Inc17.87m-210.49m4.27bn76.00--36.50--239.00-0.628-0.6280.05490.21120.068----30,206.32-71.81---89.44--36.54---1,055.85-----8.110.6748-------229.34------
Beijing Konruns Pharmaceutical Co Ltd910.05m123.44m4.29bn447.0034.111.25--4.720.73110.73115.3820.030.21781.952.901,893,258.003.815.434.486.2487.8389.9317.5220.763.36--0.058221.536.15-2.0848.24-10.6343.05-9.71
Data as of Nov 22 2024. Currency figures normalised to Beijing Luzhu Biotechnology Co Ltd's reporting currency: Hong Kong Dollar HKD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.